ADMA Biologics Hit With Securities Fraud Lawsuit Over Alleged Revenue Misrepresentations
ADMA sits 17% above its 52-week low of $7.21.
Summary
A securities fraud class action lawsuit has been filed against ADMA Biologics and its senior executives. The lawsuit alleges the company engaged in a "channel stuffing" scheme to misrepresent its 2025 revenue growth, claiming a reported 20% growth masked an actual 3% decline. This formal legal action stems from a Culper Research report in March 2026 that previously led to significant stock price declines. The lawsuit introduces material legal and financial risk, potentially impacting investor confidence despite recent positive news regarding FDA approvals and strong Q1 results. The lead plaintiff deadline is August 10, 2026.
At the time of this announcement, ADMA was trading at $8.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $7.21 to $20.46. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: PR Newswire.